Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | Mitochondrial defects in Alzheimer’s disease

Mounia Chami, PhD-HDR, Institute of Molecular and Cellular Pharmacology (IPMC), Sophia-Antipolis, France, discusses mitochondrial defects in Alzheimer’s disease (AD) and their pathological impact. Besides the deposition of amyloid-β and neurofibrillary tangles, other alterations affect the neurons. Among them are synaptic plasticity and mitochondrial dysfunction. Dr Chami states that it is essential to note that mitochondrial dysfunction has been linked to toxic amyloid-β peptides, demonstrating an interaction with different proteins and an adverse effect on mitochondrial function. Dr Chami further describes a study investigating the contribution of other fragments besides amyloid-β to mitochondrial dysfunction by analyzing mitochondrial structure, function, and mitophagy. This study demonstrated positive results whereby the observations were the same in the experimental AD models as they were in the human brain. This interview took place at the AD/PD™ 2022 conference in Barcelona, Spain.